TransMedics Group, Inc.

Total Valuation

TransMedics Group, Inc. carries a market capitalization of 2.37B, placing it among publicly traded companies globally. Its enterprise value stands at 3.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

TransMedics Group, Inc. currently has 34.55M shares outstanding.

Valuation Ratios

TransMedics Group, Inc. trades at a trailing price-to-earnings ratio of 19.75. The price-to-sales ratio is 5.34, and the price-to-book ratio stands at 6.87.

Enterprise Valuation

On an enterprise value basis, TransMedics Group, Inc. trades at an EV/EBITDA multiple of 29.82 and an EV/FCF ratio of 11.76. The EV/Sales ratio of 5.97 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 40.21 provides insight into valuation relative to core operating earnings.

Financial Position

TransMedics Group, Inc. maintains a current ratio of 6.74, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 174.78, indicating elevated leverage, while an interest coverage ratio of 7.28 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

TransMedics Group, Inc. posts a return on equity of 45.21 and a return on invested capital of 9.60.

Taxes

Over the trailing twelve months, TransMedics Group, Inc. has paid -82.59M in income taxes, reflecting an effective tax rate of 17.31.

Stock Price Statistics

TransMedics Group, Inc.'s stock has declined approximately -46.83082% over the past 52 weeks. The 50-day moving average sits at 91.64, while the 200-day moving average is 117.78.

Income Statement

Over the trailing twelve months, TransMedics Group, Inc. generated 635.89M in revenue and converted that into 171.92M in net income, yielding earnings per share of 4.34. EBITDA reached 127.35M, while operating income came in at 94.44M.

Balance Sheet

TransMedics Group, Inc. holds 461.74M in cash and equivalents against 863.42M in total debt, resulting in a net debt position of 51.46M. Total book value stands at 494.01M, with working capital of 527.36M providing operational flexibility.

Cash Flow

TransMedics Group, Inc. produced 220.23M in operating cash flow over the past twelve months. After subtracting -68.87M in capital expenditures, free cash flow totaled 151.36M - equivalent to 4.43 per share.

Margins

TransMedics Group, Inc. operates with a gross margin of 59.09, reflecting its pricing power and cost economics. The operating margin of 14.85 and net profit margin of 27.04 provide insight into operational efficiency.

Dividends & Yields

Scores

TransMedics Group, Inc. posts an Altman Z-Score of 3.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.